News - Leukaemia Care

8th September 2025

Blinatumomab approved for acute lymphoblastic leukaemia (ALL) patients

Leukaemia Care welcomes the SMC and NICE's approval of blinatumomab for wider availability to all those living with ALL, bringing hope for relapse prevention and an improved quality of life.

14th August 2025

Six months of support: Our impact in 2025 so far

In the first half of 2025, Leukaemia Care has supported thousands through counselling, financial aid, trusted information and helpline advice — ensuring no one faces leukaemia alone. Discover our impact so far and how you can access support or help us reach even more people.

9th June 2025

Dalata and Leukaemia Care extend transformative partnership to 2028

Dalata’s Difference Makers aim to raise over €1 million for health and wellbeing charities

9th June 2025

Ruxolitinib approved for patients with acute GvHD in England and Scotland

Leukaemia Care welcomes NICE and the SMC’s approval of ruxolitinib for patients with acute graft versus host disease (aGvHD) in England and Scotland.

18th March 2025

Welfare Reforms and leukaemia patients: What you need to know

The UK Government's proposed welfare reforms could negatively impact leukaemia patients relying on benefits like Universal Credit and PIP. Leukaemia Care is advocating against unfair changes that may worsen financial struggles. While some aspects remain uncertain, the charity is pushing for fairer policies and offering support to affected individuals.

12th December 2024

Leukaemia Care Winter Appeal: Wrapped wishes of gratitude, highlighting the impact of our support

This Winter, we’re wrapping gift tags around Leukaemia Care HQ, filled with heartfelt messages of support and gratitude from those who have benefited from our vital support services.

11th November 2024

Additional treatment for AML patients now available in Scotland

Leukaemia Care is pleased to announce that newly diagnosed acute myeloid leukaemia (AML) patients with a FLT3 mutation now have access to quizartinib, in combination with chemotherapy, thanks to a decision made by the Scottish Medicines Consortium (SMC) today.

31st October 2024

Leukaemia Care’s response to the 2024 Autumn Budget

"We welcome the increase in the NHS budget. However..." - Colin Dyer, Chief Executive at Leukaemia Care shares the charity's response.

22nd October 2024

NEW NHS treatment option for myelofibrosis patients

Certain patients with myelofibrosis will have access to fedratinib to treat myelofibrosis, thanks to a decision made by the National Institute for Health and Care Excellence (NICE).

4th October 2024

New treatment for patients with mastocytosis in England and Wales

Leukaemia Care and UK Masto are pleased to announce that Avapritinib (Ayvakyt©) has been approved for treating advanced systemic mastocytosis in adults in England and Wales, thanks to a decision made by the National Institute for Health and Care Excellence (NICE).